The Neurology segment focuses on the research and development of innovative drug therapies for neurological disorders, including Alzheimer's disease and Parkinson's disease. This segment's primary focus is on NE3107, a small molecule being evaluated in Phase III clinical trials for mild to moderate Alzheimer's disease and Phase I for Parkinson's disease. Research and development activities include clinical trials, biomarker analysis, and safety and efficacy studies. The segment aims to address the significant unmet medical needs of patients suffering from neurodegenerative diseases. Market positioning involves targeting specific patient populations and establishing a competitive advantage through innovative therapeutic approaches. Future opportunities include expanding the application of NE3107 to other neurological conditions and securing regulatory approvals. Partnerships and collaborations are essential for advancing clinical trials and commercialization efforts.

The Liver Disease segment is dedicated to developing treatments for chronic liver conditions, with a primary focus on ascites due to chronic liver cirrhosis. The lead product in this segment is BIV201 (terlipressin), which has completed a Phase IIa clinical trial. Research and development activities include formulation development, clinical trial management, and regulatory submissions. The segment aims to address the significant unmet medical needs of patients with advanced liver disease. The therapeutic approach involves targeting the underlying pathophysiology of ascites to improve patient outcomes. Market positioning involves targeting specific patient populations and establishing a competitive advantage through innovative therapeutic approaches. Future opportunities include expanding the application of BIV201 and securing regulatory approvals. Partnerships and collaborations are essential for advancing clinical trials and commercialization efforts.